Why the study?
Does antiplatelet therapy (aspirin, dipyridamole, or clopidogrel) prevent recurrent stroke in patients with ischemic stroke or TIA of atherosclerotic origin?
Does antiplatelet therapy (aspirin, dipyridamole, or clopidogrel) prevent recurrent stroke in patients with ischemic stroke or TIA of atherosclerotic origin?
Aspirin, aspirin plus dipyridamole, and clopidogrel are all appropriate and effective options for the secondary prevention of ischemic stroke of atherosclerotic origin.
Supports antiplatelet use for stroke prevention; leaves open optimal agent selection in atherosclerotic TIA.
Drugs that prevent platelets from sticking together-ie, aspirin, dipyridamole, and clopidogrel-are an important part of therapy to prevent recurrence of ischemic stroke of atherosclerotic origin. We discuss current indications for these drugs and review the evidence behind our current use of aspirin, dipyridamole, and clopidogrel.
No takes yet. Share an insight, caveat, or question.
Mansoor et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: